Variable | Hazard ratio (95% confidence interval) | P |
---|---|---|
Uppsala cohort | Â | Â |
Tumor size > 20 mm | 3.20 (1.65 to 6.21) | 0.0006 |
Lymph node positive | 3.13 (1.79 to 5.46) | < 0.0001 |
HER2 high expression | 1.82 (1.02 to 3.27) | 0.0444 |
HSPC111 high expression | 2.29 (1.30 to 4.03) | 0.0043 |
HSPC111 high expression | 2.51 (1.43 to 4.41) | 0.0014 |
MYC high expression | 1.89 (1.06 to 3.36) | 0.0305 |
NKI cohort | Â | Â |
Tumour size > 20 mm | 1.90 (1.10 to 3.28) | 0.0223 |
Tumour grade > 2 | 2.04 (1.22 to 3.44) | 0.0070 |
ER positive | 0.67 (0.38 to 1.18) | 0.1636 |
PR positive | 0.56 (0.32 to 1.00) | 0.0490 |
HER2 high expression | 1.46 (0.87 to 2.43) | 0.1493 |
HSPC111 high expression | 1.29 (0.79 to 2.12) | 0.3074 |
HSPC111 high expression | 1.89 (1.17 to 3.08) | 0.0097 |
MYC high expression | 1.83 (1.14 to 2.93) | 0.0118 |